|
|
| Product Name: | PL017 | | Synonyms: | (N-ME-PHE3,D-PRO4)-BETA-CASOMORPHIN (1-4) AMIDE (BOVINE);[N-ME-PHE3, D-PRO4]-MORPHICEPTIN;[(NME)PHE3, DPRO4] MORPHICEPTIN, BOVINE;PL017;TYR-PRO-(NME)PHE-DPRO-NH2;H-TYR-PRO-N-ME-PHE-D-PRO-NH2;{N-METHYL-PHE3,D-PRO4}-BETA-CASOMORPHIN FRAGMENT 1-;[n-methyl-phe3, d-pro4]-β-casomorphin fragment 1-4 amide, bovine | | CAS: | 83397-56-2 | | MF: | C29H37N5O5 | | MW: | 535.63 | | EINECS: | | | Product Categories: | | | Mol File: | 83397-56-2.mol |  |
| | PL017 Chemical Properties |
| Boiling point | 878.5±65.0 °C(Predicted) | | density | 1.313±0.06 g/cm3(Predicted) | | storage temp. | −20°C | | form | Powder | | pka | 9.86±0.15(Predicted) | | Water Solubility | Soluble to 1 mg/ml in water |
| | PL017 Usage And Synthesis |
| Biological Activity | PL-017 is a potent and selective μ opioid receptor agonist with IC50 of 5.5 nM for 125I-FK 33,824 binding to the μ site. PL-017 produces durable and reversible analgesia in rats. | | in vitro | PL-017 has an IC 50 of 10000 nM for 125 I-DADLE binding to δ site. | | in vivo | PL-017 (0.22, 0.45, 0.9 nmol/rat; icv) has the time of maximum effect of approximately 15 to 30 mm after injection at lower doses and produces analgesia lasting as long as 4 hours with larger doses in male Sprague-Dawley rats weighing 250 to 375 g. | | target | IC50: 5.5 nM ( 125 I-FK 33,824 binding to μ site) |
| | PL017 Preparation Products And Raw materials |
|